Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 3 years, the average EBITDA Per Share Growth Rate was 37.20% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 23.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of NeuroPace was 37.20% per year. The lowest was 6.30% per year. And the median was 19.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
NeuroPace 5-Year EBITDA Growth Rate Related Terms
NPCE vs KIDS, VREX, OFIX: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, NeuroPace's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where NeuroPace's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 23.50% mean?
NeuroPace (NPCE) has a 5-Year EBITDA Growth Rate of 23.50% as of Mar. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for NeuroPace and its competitors.
Is NeuroPace's 5-Year EBITDA Growth Rate too high?
NeuroPace's current 5-Year EBITDA Growth Rate is 23.50%. Overall, NeuroPace has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's 5-Year EBITDA Growth Rate compare to KIDS and VREX?
NeuroPace's 5-Year EBITDA Growth Rate of 23.50% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for NeuroPace and its competitors. NeuroPace's current 5-Year EBITDA Growth Rate is 23.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Modestly Overvalued. The stock's GF Value™ is $11.40, compared to a current price of $13.91 — trading 22% above its estimated fair value. The current 5-Year EBITDA Growth Rate is 23.50%. NeuroPace's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For NeuroPace (NPCE), the current 5-Year EBITDA Growth Rate is 23.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $13.91 is trading 22% above its estimated GF Value™ of $11.40.
GuruFocus considers NeuroPace to be Modestly Overvalued.
Key valuation signals for NPCE:
5-Year EBITDA Growth Rate: 23.50%
GF Value™: $11.40 vs. price of $13.91 (22% above fair value)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
69GF Score
Get the complete analysis for NPCE
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
